PE20191238A1 - Crenolanib para tratar mutaciones asociadas con trastornos proliferativos con flt3 mutado - Google Patents
Crenolanib para tratar mutaciones asociadas con trastornos proliferativos con flt3 mutadoInfo
- Publication number
- PE20191238A1 PE20191238A1 PE2019000923A PE2019000923A PE20191238A1 PE 20191238 A1 PE20191238 A1 PE 20191238A1 PE 2019000923 A PE2019000923 A PE 2019000923A PE 2019000923 A PE2019000923 A PE 2019000923A PE 20191238 A1 PE20191238 A1 PE 20191238A1
- Authority
- PE
- Peru
- Prior art keywords
- crenolanib
- proliferative disorders
- treat
- mutations associated
- mutated flt3
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662416475P | 2016-11-02 | 2016-11-02 | |
| US15/799,684 US11078541B2 (en) | 2016-11-02 | 2017-10-31 | Crenolanib for treating FLT3 mutated proliferative disorders associated mutations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191238A1 true PE20191238A1 (es) | 2019-09-11 |
Family
ID=62020370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019000923A PE20191238A1 (es) | 2016-11-02 | 2017-10-31 | Crenolanib para tratar mutaciones asociadas con trastornos proliferativos con flt3 mutado |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11078541B2 (enExample) |
| EP (1) | EP3359155A4 (enExample) |
| JP (3) | JP2019532011A (enExample) |
| KR (2) | KR20200079351A (enExample) |
| CN (1) | CN108778276A (enExample) |
| AU (1) | AU2017353925A1 (enExample) |
| BR (1) | BR112019008762A2 (enExample) |
| CA (1) | CA3024012A1 (enExample) |
| CL (1) | CL2019001208A1 (enExample) |
| CO (1) | CO2019005466A2 (enExample) |
| EA (1) | EA201991078A1 (enExample) |
| HK (1) | HK1257195A1 (enExample) |
| IL (1) | IL266303A (enExample) |
| MX (1) | MX2019005008A (enExample) |
| PE (1) | PE20191238A1 (enExample) |
| PH (1) | PH12019500965A1 (enExample) |
| SG (1) | SG11201903889TA (enExample) |
| WO (1) | WO2018085292A1 (enExample) |
| ZA (1) | ZA201903089B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3359155A4 (en) * | 2016-11-02 | 2019-05-22 | Arog Pharmaceuticals, Inc. | CRENOLANIB FOR THE TREATMENT OF MUTATIONS ASSOCIATED WITH FLT3-MUTED PROLIFERATIVE DISEASES |
| US12534764B2 (en) * | 2016-11-02 | 2026-01-27 | Arog Pharmaceuticals, Inc. | Crenolanib for treating FLT3 mutated proliferative disorders associated mutations |
| EP3601249A4 (en) | 2017-03-24 | 2020-12-16 | Kura Oncology, Inc. | METHODS OF TREATMENT OF MALIGNANT HEMOPATHIES AND EWING'S SARCOMA |
| US12268690B2 (en) | 2018-07-27 | 2025-04-08 | Oregon Health & Science University | Treatments for mutations in acute myeloid leukemia |
| JP2022503792A (ja) * | 2018-09-26 | 2022-01-12 | クラ オンコロジー，インク． | メニン阻害剤を用いた血液悪性腫瘍の処置 |
| CN109678849A (zh) * | 2019-01-16 | 2019-04-26 | 北京悦康科创医药科技股份有限公司 | 一种抗癌药物的制备方法 |
| US11471451B2 (en) * | 2019-08-19 | 2022-10-18 | Arog Pharmaceuticals, Inc. | Uses of crenolanib |
| CN110531016B (zh) * | 2019-09-05 | 2021-08-31 | 合肥诺明药物安全研究有限公司 | 一种hyml-122血药浓度定量分析方法 |
| CA3186319A1 (en) * | 2020-07-20 | 2022-01-27 | Arog Pharmaceuticals, Inc. | Crystal forms of crenolanib and methods of use thereof |
| WO2022019998A1 (en) | 2020-07-20 | 2022-01-27 | Arog Pharmaceuticals, Inc. | Crystal forms of crenolanib and methods of use thereof |
| US11524006B2 (en) | 2020-09-17 | 2022-12-13 | Arog Pharmaceuticals, Inc. | Crenolanib for treating TRK kinase associated proliferative disorders |
| CN112921091B (zh) * | 2021-03-16 | 2022-01-21 | 南京先声医学检验实验室有限公司 | Flt3基因突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用 |
| JP2023063189A (ja) | 2021-10-22 | 2023-05-09 | アログ・ファーマシューティカルズ・インコーポレイテッド | 以前の治療に対して再発性／不応性のｆｌｔ３突然変異増殖性障害を治療するためのクレノラニブ |
| CN115141886B (zh) * | 2022-06-28 | 2023-06-06 | 厦门艾德生物医药科技股份有限公司 | 一种基于高通量测序的髓系白血病基因突变检测的探针引物组及其应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5990146A (en) | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
| JP2001518470A (ja) | 1997-09-26 | 2001-10-16 | メルク エンド カムパニー インコーポレーテッド | 新規な血管形成阻害剤 |
| UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| CA2424689A1 (en) | 2000-10-17 | 2002-04-25 | Merck & Co., Inc. | Orally active salts with tyrosine kinase activity |
| TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
| US7101884B2 (en) | 2001-09-14 | 2006-09-05 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO2003024931A1 (en) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| TWI259081B (en) | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
| IL161156A0 (en) | 2001-10-30 | 2004-08-31 | Novartis Ag | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
| WO2003057690A1 (en) | 2001-12-27 | 2003-07-17 | Theravance, Inc. | Indolinone derivatives useful as protein kinase inhibitors |
| TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| CA2495386C (en) | 2002-08-14 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| CA2496164C (en) | 2002-08-23 | 2010-11-09 | Chiron Corporation | Benzimidazole quinolinones and uses thereof |
| PA8580301A1 (es) | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
| EP1566379A4 (en) | 2002-10-29 | 2005-11-09 | Kirin Brewery | CHINOLINE DERIVATIVES AND CHINAZOLINE DERIVATIVES AS INHIBITORS OF FLT3 AUTOPHOSPHORYLATION AND THE MEDICAL COMPOSITIONS CONTAINING THEREOF |
| CA2501932C (en) | 2002-11-13 | 2014-03-11 | Chiron Corporation | Use of benzimidazole quinolinones for treating cancer |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| ATE425160T1 (de) | 2002-12-18 | 2009-03-15 | Vertex Pharma | Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen |
| WO2004113322A1 (en) | 2003-06-24 | 2004-12-29 | Pfizer Products Inc. | Processes for the preparation of 1-[(benzoimidazole-1yl) quinolin-8-yl] piperidin-4-ylamine derivatives |
| ES2604102T3 (es) * | 2009-04-06 | 2017-03-03 | Vanda Pharmaceuticals Inc. | Método de tratamiento basado en polimorfismos del gen KCNQ1 |
| CA2867375A1 (en) * | 2012-03-12 | 2013-09-19 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia |
| KR20140040594A (ko) | 2012-09-26 | 2014-04-03 | 아로그 파마슈티칼스, 엘엘씨 | 돌연변이체 c-kit의 억제 방법 |
| BR112015016282A2 (en) | 2013-01-07 | 2017-07-11 | Arog Pharmaceuticals, Inc. | crenolanib for treatment of mutated flt3 proliferative disorders |
| EP3359155A4 (en) | 2016-11-02 | 2019-05-22 | Arog Pharmaceuticals, Inc. | CRENOLANIB FOR THE TREATMENT OF MUTATIONS ASSOCIATED WITH FLT3-MUTED PROLIFERATIVE DISEASES |
-
2017
- 2017-10-31 EP EP17866388.6A patent/EP3359155A4/en active Pending
- 2017-10-31 KR KR1020207018302A patent/KR20200079351A/ko not_active Ceased
- 2017-10-31 KR KR1020187016693A patent/KR20180074792A/ko not_active Ceased
- 2017-10-31 WO PCT/US2017/059377 patent/WO2018085292A1/en not_active Ceased
- 2017-10-31 BR BR112019008762-1A patent/BR112019008762A2/pt not_active Application Discontinuation
- 2017-10-31 JP JP2018506309A patent/JP2019532011A/ja active Pending
- 2017-10-31 MX MX2019005008A patent/MX2019005008A/es unknown
- 2017-10-31 AU AU2017353925A patent/AU2017353925A1/en not_active Abandoned
- 2017-10-31 HK HK18116172.6A patent/HK1257195A1/zh unknown
- 2017-10-31 EA EA201991078A patent/EA201991078A1/ru unknown
- 2017-10-31 US US15/799,684 patent/US11078541B2/en active Active
- 2017-10-31 PE PE2019000923A patent/PE20191238A1/es unknown
- 2017-10-31 CN CN201780016669.1A patent/CN108778276A/zh active Pending
- 2017-10-31 CA CA3024012A patent/CA3024012A1/en active Pending
- 2017-10-31 SG SG11201903889TA patent/SG11201903889TA/en unknown
-
2019
- 2019-04-29 IL IL266303A patent/IL266303A/en unknown
- 2019-04-30 PH PH12019500965A patent/PH12019500965A1/en unknown
- 2019-05-02 CL CL2019001208A patent/CL2019001208A1/es unknown
- 2019-05-17 ZA ZA2019/03089A patent/ZA201903089B/en unknown
- 2019-05-24 CO CONC2019/0005466A patent/CO2019005466A2/es unknown
-
2021
- 2021-06-23 US US17/355,468 patent/US12404555B2/en active Active
-
2022
- 2022-03-02 JP JP2022031616A patent/JP7536320B2/ja active Active
-
2024
- 2024-04-11 JP JP2024064106A patent/JP2024096859A/ja not_active Withdrawn
-
2025
- 2025-06-11 US US19/234,777 patent/US20250305063A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7536320B2 (ja) | 2024-08-20 |
| US11078541B2 (en) | 2021-08-03 |
| ZA201903089B (en) | 2019-12-18 |
| CO2019005466A2 (es) | 2019-07-31 |
| JP2024096859A (ja) | 2024-07-17 |
| US20210324481A1 (en) | 2021-10-21 |
| EP3359155A4 (en) | 2019-05-22 |
| KR20180074792A (ko) | 2018-07-03 |
| US12404555B2 (en) | 2025-09-02 |
| BR112019008762A2 (pt) | 2019-07-16 |
| MX2019005008A (es) | 2019-09-10 |
| CN108778276A (zh) | 2018-11-09 |
| EP3359155A1 (en) | 2018-08-15 |
| PH12019500965A1 (en) | 2019-12-02 |
| AU2017353925A1 (en) | 2018-09-27 |
| US20250305063A1 (en) | 2025-10-02 |
| CL2019001208A1 (es) | 2019-07-26 |
| WO2018085292A1 (en) | 2018-05-11 |
| CA3024012A1 (en) | 2018-05-11 |
| IL266303A (en) | 2019-06-30 |
| SG11201903889TA (en) | 2019-05-30 |
| US20180117031A1 (en) | 2018-05-03 |
| EA201991078A1 (ru) | 2019-11-29 |
| KR20200079351A (ko) | 2020-07-02 |
| JP2022071099A (ja) | 2022-05-13 |
| JP2019532011A (ja) | 2019-11-07 |
| HK1257195A1 (zh) | 2019-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289996A (en) | Melanocortin-4 receptor (mc4r) agonists for use in treating melanocortin-4 receptor pathway-associated disorders | |
| PE20170523A1 (es) | Formulacion en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin-6-ylmetil)imidazo[1,2- b][1,2,4]triazin-2-il]benzamida | |
| EA201890001A1 (ru) | Замещенные гетероциклические производные как ингибиторы циклинзависимой киназы (cdk) | |
| CO2018000113A2 (es) | Compuestos derivados de 2-(4-fenil-2-oxopiridin-1-(2h)-il)alcanoilamina | |
| MX389958B (es) | 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas. | |
| CO6791571A2 (es) | Moduladores de la proteína tirosina quinasa 7 (ptk7) para el tratamiento diagnóstico o profilaxis de trastornos neoplásicos | |
| MX382033B (es) | Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. | |
| MX384908B (es) | Rad1901 para usarse en el tratamiento de cáncer en sujetos con cáncer positivo a receptor de estrógeno alfa resistente a farmaco. | |
| CR20160523A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| CO2018002829A2 (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) | |
| HRP20211272T8 (hr) | 24-hidroksisteroli supstituirani na poziciji 11 za uporabu u liječenju stanja povezanih sa nmda | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| EP3400011A4 (en) | ANTI-CD20 COMBINATIONS FOR THE TREATMENT OF TUMORS | |
| ZA201607286B (en) | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders | |
| EP3419639A4 (en) | AAV IDUA VECTOR FOR TREATING BLINDNESS IN CONNECTION WITH MPS I | |
| PL3432872T3 (pl) | Eflornityna do zastosowania w leczeniu nawracającego/opornego na leczenie temozolomidem gwiaździaka anaplastycznego | |
| SI3452465T1 (sl) | Substituirani derivati 2,4-diamino-kinolina za uporabo v zdravljenju proliferativnih bolezni | |
| UY35359A (es) | 7-OXO-PIRIDO[2,3-d]PIRIMIDINAS SUSTITUIDAS Y MÉTODOS DE USO | |
| LT3687567T (lt) | Anti-adrenomedulino rišiklis, skirtas panaudoti taikant ligos simptomų terapiją arba profilaktiką | |
| MX378739B (es) | Compuestos de 2-oxindol. | |
| HUE052187T2 (hu) | Helyettesített pirido[3,4-b]indolok porcrendellenességek kezelésére | |
| AU2015295120A8 (en) | [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases | |
| BR112017021589A2 (pt) | métodos para o tratamento de transtornos cardiovasculares | |
| IT201600130012A1 (it) | Composizione per uso nel trattamento di disturbi dell'apparato uro-genitale | |
| SI3413870T1 (sl) | Igmezin za uporabo pri zdravljenju alzheimerjeve bolezni |